Combination and monotherapies in NSCLC - 102017

Spotlight
Video

Combination and monotherapies in NSCLC

VJOncology has 824 videos Subscribe Here

Loading........
Description: An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize both combination and monotherapies in clinical practice. Speaking at the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, explores how both monotherapies and combination therapies have been used with efficacy. He discusses the use of pembrolizumab, nivolumab and atezolizumab based on both PD-L1 expression status and the stage of treatment. Importantly, combinations of immunotherapies and chemotherapies are evaluated in terms of positive Phase III trials, with Dr Greystoke assessing whether this could pave the way for the future of NSLC management.
Shared By : VJOncology
Posted on : 06/21/18
Added : 12 months ago